Cytokine modulators in the treatment of sarcoidosis (Q34190083)

31 July 2017

1 reference

title

Cytokine modulators in the treatment of sarcoidosis (English)

1 reference

31 July 2017

E Bargagli

1

1 reference

31 July 2017

C Olivieri

series ordinal

2

1 reference

31 July 2017

P Rottoli

series ordinal

3

1 reference

31 July 2017

publication date

5 June 2011

1 reference

Rheumatology International

31 July 2017

published in

1 reference

31 July 2017

volume

31

1 reference

31 July 2017

issue

12

1 reference

31 July 2017

page(s)

1539-1544

1 reference

31 July 2017

cites work

Treatment of Sarcoidosis

1 reference

https://api.crossref.org/works/10.1007/S00296-011-1969-9

Sarcoidosis, role of tumor necrosis factor inhibitors and other biologic agents, past, present, and future concepts

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00296-011-1969-9

Alveolar macrophages are the main source for tumour necrosis factor-alpha in patients with sarcoidosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00296-011-1969-9

Markers of inflammation in sarcoidosis: blood, urine, BAL, sputum, and exhaled gas.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00296-011-1969-9

Increased circulating interleukin-12 (IL-12) p40 in pulmonary sarcoidosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00296-011-1969-9

Rituximab as a treatment alternative in sarcoidosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00296-011-1969-9

A systematic review of the off-label use of biological therapies in systemic autoimmune diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00296-011-1969-9

Chimeric anti-TNF-α monoclonal antibody cA2 binds recombinant transmembrane TNF-α and activates immune effector functions

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00296-011-1969-9

Treatment of sarcoidosis with infliximab

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00296-011-1969-9

Infliximab therapy in patients with chronic sarcoidosis and pulmonary involvement

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00296-011-1969-9

Effectiveness of infliximab in treating selected patients with sarcoidosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00296-011-1969-9

Treatment of CNS sarcoidosis with infliximab and mycophenolate mofetil

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00296-011-1969-9

Treating CNS sarcoidosis with infliximab and mycophenolate mofetil

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00296-011-1969-9

Switching biologic agents for uveitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00296-011-1969-9

Refractory chronic cutaneous sarcoidosis responsive to dose escalation of TNF-alpha antagonists

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00296-011-1969-9

Disseminated cryptococcal infection and anti-tumor necrosis factor-alpha treatment for refractory sarcoidosis: an expected association?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00296-011-1969-9

Changes in chest roentgenogram of sarcoidosis patients during a clinical trial of infliximab therapy: comparison of different methods of evaluation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00296-011-1969-9

Infliximab induced skin and pulmonary sarcoidosis in a rheumatoid arthritis patient.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00296-011-1969-9

Sarcoidosis appearing during anti-tumor necrosis factor alpha therapy: a new "class effect" paradoxical phenomenon. Two case reports and literature review

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00296-011-1969-9

Sarcoid-like granulomatosis in patients treated with tumor necrosis factor blockers: 10 cases

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00296-011-1969-9

The treatment of lupus pernio: results of 116 treatment courses in 54 patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00296-011-1969-9

Etanercept therapy in rheumatoid arthritis. A randomized, controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00296-011-1969-9

Etanercept for the treatment of stage II and III progressive pulmonary sarcoidosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00296-011-1969-9

Uveitis associated with sarcoidosis exacerbated by etanercept therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00296-011-1969-9

Systemic sarcoidosis with bone marrow involvement responding to therapy with adalimumab: a case report

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00296-011-1969-9

Steroid-unresponsive neurosarcoidosis successfully treated with adalimumab

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00296-011-1969-9

Adalimumab-induced noncaseating granuloma in the bone marrow of a patient being treated for rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00296-011-1969-9

Cutaneous sarcoidosis occurring during anti-TNF-alpha treatment: report of two cases

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00296-011-1969-9

Targeting the TNF-alpha pathway in sarcoidosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00296-011-1969-9

Apremilast, a cAMP phosphodiesterase-4 inhibitor, demonstrates anti-inflammatory activity in vitro and in a model of psoriasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00296-011-1969-9

Novel TNF antagonists for the treatment of rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00296-011-1969-9

Thalidomide reduces tumour necrosis factor-alpha production by human alveolar macrophages.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00296-011-1969-9

Treatment of cutaneous and pulmonary sarcoidosis with thalidomide.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00296-011-1969-9

Thalidomide for chronic sarcoidosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00296-011-1969-9

Thalidomide derived immunomodulatory drugs (IMiDs) as potential therapeutic agents

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00296-011-1969-9

Thalidomide dramatically improves the symptoms of early-onset sarcoidosis/Blau syndrome: its possible action and mechanism

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00296-011-1969-9

Pentoxifylline inhibits TNF-alpha production from human alveolar macrophages

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00296-011-1969-9

Inhibition of cytokine release from alveolar macrophages in pulmonary sarcoidosis by pentoxifylline: comparison with dexamethasone

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00296-011-1969-9

Ustekinumab: lessons learned from targeting interleukin-12/23p40 in immune-mediated diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00296-011-1969-9

Comparison of ustekinumab and etanercept for moderate-to-severe psoriasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00296-011-1969-9

Targeting the interleukin-12/23 cytokine family in the treatment of psoriatic disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00296-011-1969-9

Novel targeted therapies for autoimmunity

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00296-011-1969-9

Tolerance and short term efficacy of rituximab in 43 patients with systemic autoimmune diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00296-011-1969-9

Adalimumab: human recombinant immunoglobulin g1 anti-tumor necrosis factor monoclonal antibody

21 January 2018

1 reference

12 December 2020

Relapse of severe sarcoidosis with an uncommon peritoneal location after TNFalpha blockade. Efficacy of rituximab, report of a single case

1 reference

12 December 2020

Sarcoidosis: immunopathogenetic concepts and their clinical application

1 reference

12 December 2020

Interstitial lung disease guideline: the British Thoracic Society in collaboration with the Thoracic Society of Australia and New Zealand and the Irish Thoracic Society

1 reference

12 December 2020

Efficacy of infliximab in extrapulmonary sarcoidosis: results from a randomised trial

1 reference

12 December 2020

Infliximab for refractory sarcoidosis.

1 reference

12 December 2020

Update on the treatment of peripheral arthritis in psoriatic arthritis

1 reference

12 December 2020

The use of infliximab in cutaneous sarcoidosis

1 reference

12 December 2020

Chronic sarcoid arthritis treated with intraarticular etanercept

1 reference

12 December 2020

A double-blinded, randomized, placebo-controlled trial of infliximab in subjects with active pulmonary sarcoidosis

1 reference

12 December 2020

Etanercept for refractory ocular sarcoidosis: results of a double-blind randomized trial

1 reference

12 December 2020

Tumor necrosis factor inhibition as a novel treatment for refractory sarcoidosis

1 reference

12 December 2020

Significance of the interleukin-1 receptor antagonist/interleukin-1 beta ratio as a prognostic factor in patients with pulmonary sarcoidosis

1 reference

12 December 2020

Adalimumab for treatment of cutaneous sarcoidosis

1 reference

12 December 2020

Infliximab therapy rescues cyclophosphamide failure in severe central nervous system sarcoidosis

1 reference

12 December 2020

Release of tumor necrosis factor by alveolar macrophages of patients with sarcoidosis

1 reference

12 December 2020

Etanercept ameliorates sarcoidosis arthritis and skin disease

1 reference

12 December 2020

[Anti-TNFalpha therapy in systemic autoimmune and/or inflammatory diseases]

1 reference

12 December 2020

Treatment of sarcoidosis

1 reference

12 December 2020

Golimumab for severe asthma

1 reference

12 December 2020

Thalidomide reduces IL-18, IL-8 and TNF-alpha release from alveolar macrophages in interstitial lung disease

1 reference

12 December 2020

Treatment of therapy-resistant sarcoidosis with adalimumab.

1 reference

12 December 2020

Ulcerative cutaneous sarcoidosis responding to adalimumab

1 reference

12 December 2020

Inhibitors of tumor necrosis factor (TNF) in sarcoidosis: who, what, and how to use them

1 reference

12 December 2020

[Adalimumab in the treatment of parotid sarcoidosis]

1 reference

12 December 2020

Infliximab in chronic ocular inflammation

1 reference

12 December 2020

ATS/ERS/WASOG statement on sarcoidosis. American Thoracic Society/European Respiratory Society/World Association of Sarcoidosis and other Granulomatous Disorders

1 reference

12 December 2020

Exaggerated TNFalpha release of alveolar macrophages in corticosteroid resistant sarcoidosis

1 reference

12 December 2020

Refractory neurosarcoidosis responsive to infliximab

1 reference

12 December 2020

Abrupt development of sarcoidosis with a prodromal increase in plasma osteopontin in a patient with rheumatoid arthritis during treatment with etanercept

1 reference

12 December 2020

IL-12 and IL-18 are increased and stimulate IFN-gamma production in sarcoid lungs

1 reference

12 December 2020

IL-12 in lung diseases

1 reference

12 December 2020

Allergic bronchopulmonary aspergillosis after infliximab therapy for sarcoidosis: a potential mechanism related to T-helper cytokine balance.

1 reference

12 December 2020

Facial granulomatous nodules during etanercept treatment for psoriasis

1 reference

12 December 2020

Pentoxifylline in treatment of sarcoidosis

1 reference

12 December 2020

Lung sarcoidosis induced by TNF antagonists in rheumatoid arthritis: a case presentation and a literature review.

1 reference

12 December 2020

Sarcoidosis: TNF-alpha release from alveolar macrophages and serum level of sIL-2R are prognostic markers

1 reference

12 December 2020

The effect of thalidomide on corticosteroid-dependent pulmonary sarcoidosis

1 reference

12 December 2020

Successful treatment of steroid-refractory neurosarcoidosis with infliximab

1 reference

12 December 2020

Sarcoid sacroiliitis: successful treatment with infliximab

1 reference

12 December 2020

10.1007/S00296-011-1969-9

Identifiers

DOI

1 reference

Dimensions Publication ID

31 July 2017

1041358361

0 references

1 reference